Cell Death & Disease:c-FLIP和CD95对肾细胞癌的生存是必需的

2019-05-26 AlexYang MedSci原创

透明细胞肾细胞癌(ccRCC)是肾脏癌症中最突出的肿瘤。肾细胞癌(RCC)岁肿瘤治疗的抗性可以归结于抗凋亡蛋白的过表达而引起的细胞凋亡的抗性等。然而,在ccRCC中,关于细胞凋亡抑制因子c-FLIP的作用和它对死亡受体诱导的细胞凋亡的影响所知甚少。最近,有研究人员阐释了c-FLIP在4个ccRCC细胞系中对CD95L诱导的细胞凋亡抗性的产生非常关键。明显的是,shRNA对c-FLIP表达的下调作用

透明细胞肾细胞癌(ccRCC)是肾脏癌症中最突出的肿瘤。肾细胞癌(RCC)岁肿瘤治疗的抗性可以归结于抗凋亡蛋白的过表达而引起的细胞凋亡的抗性等。然而,在ccRCC中,关于细胞凋亡抑制因子c-FLIP的作用和它对死亡受体诱导的细胞凋亡的影响所知甚少。

最近,有研究人员阐释了c-FLIP在4个ccRCC细胞系中对CD95L诱导的细胞凋亡抗性的产生非常关键。明显的是,shRNA对c-FLIP表达的下调作用能够导致自发的凋亡蛋白的激活和细胞凋亡引起的细胞死亡。另外,所有c-FLIP剪接体的敲除对诱导细胞凋亡是需要的。CD95L刺激ccRCCx细胞能够诱导NF-κB和MAP激酶生存途径,具体是通过RelA/p65和Erk1/2的磷酸化。有趣的是,CD95L表面表达在所有分析的细胞系中较高,并且CD95而不是TNF-R1,在细胞接触未知积累。CD95下调和NF-κB途径的抑制能够导致自发性的细胞死亡。令人惊讶的是,敲除试验阐释了c-FLIP在CD95信号中能够抑制NF-κB激活。因此,c-FLIP能够抑制细胞凋亡和CD95的下游因子NF-κB,但是允许NF-κB激活到一个满足ccRCC细胞生存的水平。

最后,研究人员指出,他们阐释了一个复杂的CD95-FLIP-NF-κB信号回路,其中CD95-CD95L互作能够调节ccRCC细胞中的旁分泌信号途径,且c-FLIP和NF-κB对抑制细胞死亡和确保存活是必需的。他们的研究可能为绕过细胞凋亡抗性而开发新的RCC治疗方法提供依据。

原始出处:

Tobias Luebke, Lisa Schwarz, Yan Yan Beer et al. c-FLIP and CD95 signaling are essential for survival of renal cell carcinoma. Cell Death & Disease. 16 May 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1978846, encodeId=f49819e88466a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri May 08 01:47:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871293, encodeId=5aea18e1293d4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 17 05:47:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961576, encodeId=b29019615e6eb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jun 01 15:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013017, encodeId=530f201301edb, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jul 08 11:47:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782761, encodeId=c7f71e8276109, content=<a href='/topic/show?id=761343e74e' target=_blank style='color:#2F92EE;'>#CD95#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4377, encryptionId=761343e74e, topicName=CD95)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Sep 16 01:47:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531469, encodeId=4fa7153146987, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue May 28 11:47:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1978846, encodeId=f49819e88466a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri May 08 01:47:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871293, encodeId=5aea18e1293d4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 17 05:47:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961576, encodeId=b29019615e6eb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jun 01 15:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013017, encodeId=530f201301edb, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jul 08 11:47:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782761, encodeId=c7f71e8276109, content=<a href='/topic/show?id=761343e74e' target=_blank style='color:#2F92EE;'>#CD95#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4377, encryptionId=761343e74e, topicName=CD95)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Sep 16 01:47:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531469, encodeId=4fa7153146987, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue May 28 11:47:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1978846, encodeId=f49819e88466a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri May 08 01:47:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871293, encodeId=5aea18e1293d4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 17 05:47:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961576, encodeId=b29019615e6eb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jun 01 15:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013017, encodeId=530f201301edb, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jul 08 11:47:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782761, encodeId=c7f71e8276109, content=<a href='/topic/show?id=761343e74e' target=_blank style='color:#2F92EE;'>#CD95#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4377, encryptionId=761343e74e, topicName=CD95)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Sep 16 01:47:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531469, encodeId=4fa7153146987, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue May 28 11:47:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
    2019-06-01 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1978846, encodeId=f49819e88466a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri May 08 01:47:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871293, encodeId=5aea18e1293d4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 17 05:47:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961576, encodeId=b29019615e6eb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jun 01 15:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013017, encodeId=530f201301edb, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jul 08 11:47:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782761, encodeId=c7f71e8276109, content=<a href='/topic/show?id=761343e74e' target=_blank style='color:#2F92EE;'>#CD95#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4377, encryptionId=761343e74e, topicName=CD95)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Sep 16 01:47:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531469, encodeId=4fa7153146987, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue May 28 11:47:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1978846, encodeId=f49819e88466a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri May 08 01:47:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871293, encodeId=5aea18e1293d4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 17 05:47:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961576, encodeId=b29019615e6eb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jun 01 15:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013017, encodeId=530f201301edb, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jul 08 11:47:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782761, encodeId=c7f71e8276109, content=<a href='/topic/show?id=761343e74e' target=_blank style='color:#2F92EE;'>#CD95#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4377, encryptionId=761343e74e, topicName=CD95)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Sep 16 01:47:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531469, encodeId=4fa7153146987, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue May 28 11:47:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
    2019-09-16 habb
  6. [GetPortalCommentsPageByObjectIdResponse(id=1978846, encodeId=f49819e88466a, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Fri May 08 01:47:00 CST 2020, time=2020-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871293, encodeId=5aea18e1293d4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Nov 17 05:47:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961576, encodeId=b29019615e6eb, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sat Jun 01 15:47:00 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013017, encodeId=530f201301edb, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Mon Jul 08 11:47:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782761, encodeId=c7f71e8276109, content=<a href='/topic/show?id=761343e74e' target=_blank style='color:#2F92EE;'>#CD95#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4377, encryptionId=761343e74e, topicName=CD95)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Mon Sep 16 01:47:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531469, encodeId=4fa7153146987, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Tue May 28 11:47:00 CST 2019, time=2019-05-28, status=1, ipAttribution=)]
    2019-05-28 cy0328

相关资讯

Oncogene:UHRF1能够通过对TXNIP的表观调控促进肾细胞癌的恶化

UHRF1是一个重要的表观遗传调控因子,且属于UHRF家族。UHRF1的过表达在许多类肿瘤中存在,并且其过表达与某些癌症类型的不良预后和更短的生存相关。然而,其在肾细胞癌(RCC)中的功能仍旧不清楚。最近,有研究人员报道了RCC肿瘤组织比正常肾组织具有明显更高的UHRF1表达。siRNA或者shRNA引起的UHRF1表达的下调在RCC细胞系中能够导致细胞生存力减少、抑制细胞迁移和侵入,以及增加细胞

2019 EAU指南:肾细胞癌(更新版)

2019年2月,欧洲泌尿外科学会(EAU)更新发布了肾细胞癌指南,指南主要内容涉及肾细胞癌的管理,包括诊断分期,分类和预后因素,其他肾脏肿瘤,局部肾肿瘤的治疗,转移性肾肿瘤的系统治疗,监测随访。

Brit J Cancer:肾细胞癌中apelin和apelin受体表达研究

APLNR(apelin受体)是癌症免疫治疗的一个潜在的基因,APLNR的缺失能够导致免疫治疗的失败。最近,有研究人员调查了肾细胞肿瘤(RCC)患者中APLN(apelin)和APLNR的表达,并调查了与临床病理参数和生存的相关性。研究包括了3个详细鉴定过的RCC患者群体:研究群体1(透明细胞RCC;APLN/APLNR mRNA表达;n=166);TCGA验证群体(透明细胞RCC;APLN/AP

Nat Commun:GPX4依赖的癌细胞状态是透明细胞表型的基础并与细胞铁死亡有关

透明细胞肿瘤(CCCs)是一种高度恶性化的组织,通常起源于肾脏和卵巢。CCCs可以通过异常的脂糖原积累来区分,并且对很多抗癌疗法具有耐受性。最近, 有研究人员鉴定了固有的细胞铁死亡脆弱性与CCCs中独特的细胞代谢状态有关。该脆弱性超越了家系和遗传背景,并且可以通过利用细胞分子来抑制谷胱甘肽过氧化物酶(GPX4)来进行研究。研究人员利用CRISPR筛选和脂质体分析,研究人员鉴定了缺氧诱导因子(HIF

Cell Death & Disease:肾细胞癌中RBCK1能够通过泛素化途径促进p53降解

肾细胞癌(RCC)大约占据了成年人肿瘤的3%,并且RCC的发生率在世界范围内持续增长。尽管RCC可以在早期阶段通过外科手术来进行治疗,而在晚期患者中5年的生存率却急剧的减少。大多数接受细胞毒性或者靶向药物治疗的RCC患者在治疗期间会在某个时间点产生抗性。因此,鉴定新的RCC治疗靶标是非常必要的。最近,有研究人员发现RANBP2型和包含锌指结构 C3HC4型蛋白 (RBCK1)在人类RCC患者样本中

K药再拓疆土——细数晚期肾癌靶向治疗现状

近日,美国食品和药物管理局FDA批准Pembrolizumab (Keytruda,俗称K药)联合Inlyta(axitinib,阿昔替尼)用于晚期肾细胞癌(RCC)患者的一线治疗。Inlyta由辉瑞研发,是一种抑制血管内皮生长因子(VEGF)受体1、2、3的酪氨酸激酶抑制剂。Keytruda与Inlyta构成的组合疗法,作为一线疗法治疗晚期RCC患者,是继nivolumab与ipilimumab